

FORM PTO-1449
(REV. 7-80).ATTY. DOCKET NO.
NYU93-01M2SERIAL NO.
08/192,861INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

APPLICANT
Junming Le et al.FILING DATE
February 4, 1994

GROUP 1806

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
AA	AA	4,603,106	07/29/86	Cerami et al.	435	7	
AB	AB	4,822,776	04/18/89	Cerami et al.	514	21	
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
AL	AL	0212489A2	04.03.87	EPO	C07K	13/00	
AM	AM	0218868A2	22.04.87	EPO	C12P	21/02	
AN	AN	0288088A2	26.10.88	EPO	G01N	33/68	
AO	AO	0308378A2	22.03.89	EPO	C12N	15/00	
AP	AP	0380068A1	01.08.90	EPO	C12N	15/85	
AQ	AQ	0393438A3	24.10.90	EPO	C12N	15/12	X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AR	AR	Beutler, B. et al., "Identity of tumour necrosis factor and the macrophage-secreted factor cachectin," Nature, 316:552-554 (1985).
AS	AS	Beutler, B. et al., "Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin," Science, 229:869-871 (1985).
AT	AT	Morrison, Sherie L., "Transfectomas Provide Novel Chimeric Antibodies," Science, 229:1202-1207 (1985).

EXAMINER

DATE CONSIDERED

N. Gol
~~11/30/91~~ ~~12/3/95~~ 10/27/98

FORM PTO-1449
(REV. 7-80)INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
NYU93-01M2SERIAL NO.
08/192,861APPLICANT
Junming Le et al.FILING DATE
February 4, 1994GROUP
1806

FOREIGN PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
AL	AL2	0398327A1	22.11.90	EPO	C12P	21/02	
AM	AM2	0412486A1	13.02.91	EPO	C12P	21/08	
AN	AN2	0433900A1	26.06.91	EPO	C12A	15/12	
AO	AO2	0526905A2	10.02.93	EPO	C12A	15/12	
AP	AP2	WO91/02078	21.02.91	PCT	C12P	21/06	
AQ	AQ2	WO92/07076	30.04.92	PCT	C12A	15/12	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

LI	AU	Liang, Chi-Ming et al., "Production and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor/Cachectin," <i>Biochem. & Biophys. Res. Comm.</i> , 137(2):847-854 (1986)
HI	AV	Hirai, Makoto et al., "Production and characterization of monoclonal antibodies to human tumor necrosis factor," <i>J. of Immun. Methods</i> , 96:57-62 (1987)
PI	AW	Piguet, Pierre-Francois et al., "Tumor Necrosis Factor/Cachectin is an Effector of Skin and Gut Lesions of the Acute Phase of Graft-vs.-Host Disease," <i>J. Exp. Med.</i> , 166:1280-1289 (1987)
ME	AX	Meager, Anthony et al., "Preparation and Characterization of Monoclonal Antibodies Directed Against Antigenic Determinants of Recombinant Human Tumour Necrosis Factor (rTNF)," <i>Hybridoma</i> , 6(3):305-311 (1987)
FE	AY	Fendly, Brian M. et al., "Murine Monoclonal Antibodies Defining Neutralizing Epitopes on Tumor Necrosis Factor," <i>Hybridoma</i> , 6(4):359-370 (1987)
BR	AZ	Bringman, Timothy S. and Aggarwal, Bharat B., "Monoclonal Antibodies to Human Tumor Necrosis Factors Alpha and Beta: Applications for Affinity Purification, Immunoassays, and as Structural Probes," <i>Hybridoma</i> , 6(5):489-507 (1987)
TR	AR2	Tracey, Kevin J. et al., "Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia," <i>Nature</i> , 330:662-664 (1987)
NA	AS2	Nagai, M. et al., "Antibody to tumor necrosis factor (TNF) reduces endotoxin fever," <i>Experientia</i> , 44:606-607 (1988).

EXAMINER

DATE CONSIDERED

N. Jol *ATB/BET* *12/7/95* *10/27/98*

FORM PTO-1449
(REV. 7-80).INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
NYU93-01M2SERIAL NO.
08/192,861APPLICANT
Junming Le et al.FILING DATE
February 4, 1994

GROUP 1806

FOREIGN PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AL3	WO92/13095	06.08.92	PCT			
<i>AKS</i>	AM3	0260610A2	23.03.88	EPO	<i>ER2P</i>	<i>21/60</i>	X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>AKS</i>	AT2	Shimamoto, Yoshinori et al., "Monoclonal antibodies against human recombinant tumor necrosis factor: prevention of endotoxic shock," <i>Immunology Letters</i> , 17:311-318 (1988)
	AU2	Di Giovine, Francesco, S. et al., "Tumour necrosis factor in synovial exudates," <i>Annals of the Rheumatic Diseases</i> , 47:768-772 (1988)
<i>AKS</i>	AV2	Collins, M.S. et al., "Immunoprophylaxis of Polymicrobial Cellulitis with a Human Monoclonal Antibody Against Lipopolysaccharide Antigen of Pseudomonas aeruginosa," Abstract E-63, <i>Abstracts of Annual Meeting 1989</i>
<i>AKS</i>	AW2	Exley, A.R. et al., "Monoclonal Antibody (Mab) to Recombinant Human Tumour Necrosis Factor (rhTNF) in the Prophylaxis and Treatment of Endotoxic Shock in Cynomolgus Monkeys," <i>Medical Research Society</i> , Abstract 184, p. 50 (1989)
<i>AKS</i>	AX2	Cross, A.S. et al., "Pretreatment with Recombinant Murine Tumor Necrosis Factor α /Cachectin and Murine Interleukin 1 α Protects Mice from Lethal Bacterial Infection," <i>J of Exp Med.</i> , 169:2021-2027 (1989)
<i>AKS</i>	AY2	Engelmann, Hartmut et al., "A Tumor Necrosis Factor-binding Protein Purified to Homogeneity from Human Urine Protects Cells from Tumor Necrosis Factor Toxicity," <i>J. of Bio. Chem.</i> , 264(20):11974-11980 (1989)
<i>AKS</i>	AZ2	Kawasaki, Hajime et al., "Analysis of Endotoxin Fever in Rabbits by Using a Monoclonal Antibody to Tumor Necrosis Factor (Cachectin)," <i>Infection and Immunity</i> , 57(10):3131-3135 (1989)
<i>AKS</i>	AR3	Fong, Yuman et al., "Antibodies to Cachectin/Tumor Necrosis Factor Reduce Interleukin 1 β and Interleukin 6 Appearance During Lethal Bacteremia," <i>J. Exp. Med.</i> , 170:1627-1633 (1989)

EXAMINER

DATE CONSIDERED

10/27/98

N. Gol
*11/3/95**12/7/95*

FORM PTO-1449
(REV. 7-80)INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
NYU93-01M2SERIAL NO.
08/192,861APPLICANT
Junming Le et al.FILING DATE
February 4, 1994GROUP
1806

FOREIGN PATENT DOCUMENTS

EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

FEB 7 1995
GROUP 1800

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AS3	Von Asmuth, E.J.U. et al., "Tumour Necrosis Factor Alpha (TNF- α) and Interleukin 6 in a Zymosan-Induced Shock Model," <i>Scand. J. Immunol.</i> , 32:313-319 (1990)
AT3	Herve, P. et al., "Monoclonal Anti TNF α Antibody for the Treatment of Severe Acute GvHD in Humans," <i>Abstract 3.25, Lymphoma Res.</i> 9:591 (1990)
AU3	Silva, Ayona T. et al., "Prophylactic and Therapeutic Effects of a Monoclonal Antibody to Tumor Necrosis Factor- α in Experimental Gram-Negative Shock," <i>J. of Infectious Diseases</i> , 162:421-427 (1990)
AV3	Opal, Steven M. et al., "Efficacy of a Monoclonal Antibody Directed Against Tumor Necrosis Factor in Protecting Neutropenic Rats from Lethal Infection with <i>Pseudomonas aeruginosa</i> ," <i>J. of Infectious diseases</i> , 161:1148-1152 (1990)
AW3	Tavernier, Jan et al., "Analysis of the Structure-Function Relationship of Tumour Necrosis Factor. Human/Mouse Chimeric TNF Proteins: General Properties and Epitope Analysis," <i>J. Mol. Biol.</i> , 211:493-501 (1990)
AX3	Lucas, R. et al., "Generation and characterization of a neutralizing rat anti-rm TNF- α monoclonal antibody," <i>Immunology</i> , 71:218-223 (1990)
AY3	Hinshaw, L.B. et al., "Survival of Primates in LD ₁₀₀ Septic Shock Following Therapy with Antibody to Tumor Necrosis Factor (TNF α)," <i>Circulatory Shock</i> , 30:279-292 (1990)
AZ3	Nophar, Yaron et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type 1 TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor," <i>The EMBO Journal</i> , 9(10):3269-3278 (1990)

EXAMINER

DATE CONSIDERED

11/30/94 12/7/95 10/27/98

FORM PTO-1449
(REV. 7-80)INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
NYU93-01M2SERIAL NO.
08/192,861APPLICANT
Junming Le et al.FILING DATE
February 4, 1994GROUP
1806

FOREIGN PATENT DOCUMENTS

EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

WAS	AR4	Engelmann, Hartmut et al., "Two Tumor Necrosis Factor-binding Proteins Purified from Human Urine," <i>J. of Bio. Chem.</i> , 265(3):1531-1536 (1990)
h	AS4	Verhoef, J. and Torensma, R., "Prospects for Monoclonal Antibodies in the Diagnosis and Treatment of Bacterial Infections," <i>Eur. J. Clin. Microbiol. Dis.</i> , 9(4):247-250 (1990)
h	AT4	Loetscher, Hansruedi et al., "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor," <i>Cell</i> , 61:351-359 (1990)
h	AU4	Schall, Thomas J. et al., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor," <i>Cell</i> , 61:361-370 (1990)
h	AV4	Akama, Hideto et al., "Mononuclear Cells Enhance Prostaglandin E ₂ Production of Polymorphonuclear Leukocytes via Tumor Necrosis Factor α ," <i>Biochemical and Biophysical Research Comm.</i> , 168(2):857-862 (1990)
h	AW4	Exley, A.R. et al., "Monoclonal antibody to TNF in severe septic shock," <i>The Lancet</i> , 335:1275-1277 (1990)
h	AX4	Möller, Achim et al., "Monoclonal Antibodies to Human Tumor Necrosis Factor α : In Vitro and In Vivo Application," <i>Cytokine</i> , 2(3):162-169 (1990)
h	AY4	Ruddle, Nancy H. et al., "An Antibody to Lymphotoxin and Tumor Necrosis Factor Prevents Transfer of Experimental Allergic Encephalomyelitis," <i>J. Exp. Med.</i> , 172:1193-1200 (1990)

EXAMINER

DATE CONSIDERED

W. O. P. / 12/7/95 10/27/98

FORM PTO-1449
(REV. 7-80)INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
NYU93-01M2SERIAL NO.
08/192,861APPLICANT
Junming Le et al.FILING DATE
February 4, 1994

GROUP 1806

FOREIGN PATENT DOCUMENTS

EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

WAS	AZ4	Galloway, Cynthia J. et al., "Monoclonal anti-tumor necrosis factor (TNF) antibodies protect mouse and human cells from TNF cytotoxicity," <i>J. of Immunological Methods</i> , 140:37-43 (1991)
WAS	AR5	Waldmann, Thomas A., "Monoclonal Antibodies in Diagnosis and Therapy," <i>Science</i> , 252:1657-1662 (1991)
WAS	AS5	Aderka, Dan et al., "The Possible Role of Tumor Necrosis Factor (TNF) and Its Natural Inhibitors, The Soluble-TNF Receptors, In Autoimmune Diseases," <i>Israel J. Med. Sci.</i> , 28(2):126-130 (1992)
WAS	AT5	Pennington, James, "TNF: Therapeutic Target in Patients with Sepsis," <i>ASM News</i> , 58(9):479-482 (1992)
WAS	AU5	Harris, William J. and Emery, Steven, "Therapeutic antibodies - the coming of age," TBTECH , 11:42-44 (1993) TIBTECH
WAS	AV5	Parrillo, Joseph E., "Pathogenetic Mechanisms of Septic Shock," <i>N.E. Journal of Medicine</i> , 328(20):1471-1477 (1993)
WAS	AW5	Aggarwal, Bharat B. et al., "Human Tumor Necrosis Factor Production, Purification and Characterization," <i>J. of Biol. Chem.</i> , 260(4):2345-2354 (1985)
WAS	AX5	Beutler, B. et al., "Purification of Cachectin, A Lipoprotein Lipase-Suppressing Hormone Secreted by Endotoxin-induced RAW 264.7 Cells," <i>J. Exp. Med.</i>, 161:984-995 (1985)

EXAMINER

DATE CONSIDERED

N-90
N/3PE10/27/98
12/7/95

FORM PTO-1449
(REV. 7-80).INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
NYU93-01M2SERIAL NO.
08/192,861APPLICANT
Junming Le et al.FILING DATE
February 4, 1994GROUP
1806

FOREIGN PATENT DOCUMENTS

EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AY5	Echtenacher, Bernd et al., "Requirement of Endogenous Tumor Necrosis Factor/Cachectin for Recovery from Experimental Peritonitis," <i>J. of Immunology</i> , 145(11):3762-3766 (1990)
AZ5	Smith, Craig R., "Human and Chimeric Antibodies to LPS and TNF," Abstract, <i>Endotoxemia & Sepsis Conference</i> (1991)
AR6	Bodmer, Mark, "Humanized Antibodies for Anti-TNF Therapy," Abstract, <i>Endotoxemia & Sepsis Conference</i> (1991)

EXAMINER

DATE CONSIDERED

10/27/98

12/7/95

FORM PTO-14
(REV. 7-80)ATTY. DOCKET NO.
NYU93-01M2SERIAL NO.
08/192,861INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

APPLICANT
Junming Le et al.FILING DATE
February 4, 1994GROUP
1806

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						



FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
/	AN3	91/09967	11.07.91	PCT			
X	AO3	0351789A2	24.01.90	EPO			
/	AP3	0350690A2	17.01.90	EPO			X
/	AQ3	90/00902	08.02.90	PCT			
	AR3						
	AS3						

*Duplicate
listing*

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

10/27/98
12/7/95
15BBT

FORM PTO-1449
(REV. 7-80)INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
NYU93-01M2SERIAL NO.
08/192,861APPLICANT
Junming Le et al.FILING DATE
February 4, 1994GROUP
1806

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

REC
11/27
GROUP 1800

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
<i>JS</i>	AN3	91/09967	11.07.91	PCT	—	—	
<i>JS</i>	AO3	0351789A2	24.01.90	EPO	—	—	
<i>JS</i>	AP3	0350690A2	17.01.90	EPO	—	—	X
<i>JS</i>	AQ3	90/00902	08.02.90	PCT	—	—	
	AR3						
	AS3						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

N. John 10/27/98
4/11/97